cxrx stock price on yahoo finance

Is Xerox (XRX) a large cap stock?

Xerox Holdings Corporation ( NASDAQ:XRX ), might not be a large cap stock, but it received a lot of attention from a... NORWALK, Conn., November 02, 2021--Xerox announced the new Xerox Workflow Central, a secure, cloud-based software platform providing access to workflow automation and digitization tools

When does Xerox Holdings Corporation stock pay a dividend?

NORWALK, Conn., November 30, 2021--Xerox Holdings Corporation announced today that the company will participate in two upcoming investor events on December 6 and December 13. The board of Xerox Holdings Corporation ( NASDAQ:XRX ) has announced that it will pay a dividend on the 31st of...

What does cmrx stand for?

Chimerix (CMRX), a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases, today announces an exclusive global license agreement...

Who is XRX?

The printing and digital document products and services provider Xerox Holdings (XRX) revealed the acquisition of document solutions provider Document Systems in an effort to increase its presence in the U.S. small and midsize business (SMB) market. Transaction terms remained undisclosed. Joanne Collins Smee, Chief Commercial, SMB, and Channels Officer at Xerox said, “We are focused on strengthening our U.S. SMB market reach through the combined power of our portfolio of workplace solutions for

When did Xerox join Gartner?

NORWALK, Conn., October 06, 2021 --Xerox announced today that it joined the Gartner Peer Insights Customer First Program and earned the Customer First Badge.

Is Xerox a dividend stock?

Xerox (NYSE: XRX) seems like a cheap dividend stock on the surface. It's a Fortune 500 company that provides print and digital document products and services across 160 countries, its stock trades at just 11 times forward earnings, and it pays a high forward dividend yield of 4.

How much is Chimerix losing in 2020?

During the same period in 2020, Chimerix recorded a net loss of $10.4 million, or $0.17 per basic and diluted share. Revenues for the first quarter of 2021 increased to $1.4 million, compared to $1.2 million for the same period in 2020.

What is Chimerix's business?

DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET. A live audio webcast of the chat will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The Company’s three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT). BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia. CONTACT: Investor Relations:Michelle LaSpaluto919 [email protected] O’ConnorStern Investor [email protected]

What is Chimerix 2021?

DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a fireside chat at the Cowen and Company 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 10:00 a.m. ET. A live audio webcast of the chat will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT). BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. CONTACT: Investor Relations: Michelle LaSpaluto919 [email protected] O’ConnorStern Investor [email protected]

What is chimerix biopharmaceutical?

About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.

How to access a conference call on Chimerix?

To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 5156727. A live audio webcast of the call will also be available on the Investors section of Chimerix’s website, www.chimerix.com.

ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis

YONKERS, N.Y., Jan.

How Much Of ContraFect Corporation (NASDAQ:CFRX) Do Institutions Own?

A look at the shareholders of ContraFect Corporation ( NASDAQ:CFRX ) can tell us which group is most powerful...

What Is The Ownership Structure Like For CareRx Corporation (TSE:CRRX)?

Every investor in CareRx Corporation ( TSE:CRRX ) should be aware of the most powerful shareholder groups. Institutions...

When will CareRx end?

CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of pharmacy services to seniors communities, today reported its financial results for the first quarter ended March 31, 2021.

What is CareRx Corporation?

CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, announced today that it has closed the previously announced transaction to acquire Rexall Pharmacy Group's ("Rexall") long-term care pharmacy business in Ontario and Northern Alberta (the "Transaction").

When will the TSX close in 2021?

The Equity Financings are expected to close on or about May 19, 2021 and are each subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Toronto Stock Exchange (the “TSX”).

When is CareRx earnings call 2021?

NEW YORK, NY / ACCESSWIRE / May 13, 2021 / CareRx Corp. (TSX:CRRX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 8:30 AM Eastern Time.

What is Think Research Corporation?

Think Research Corporation (TSXV: THNK) ("Think" or the "Company"), a company focused on transforming healthcare through digital health software solutions, is pleased to announce today it has expanded its partnership with CareRx Corporation ("CareRx") (TSX: CRRX), Canada's leading provider of pharmacy services to seniors, to deliver virtual healthcare to residents in Chartwell Retirement Residences ("Chartwell") (TSE: CSH.UN). This expansion follows a successful pilot project in select Chartwell

Who are some of (CXRX)'s key competitors?

Some companies that are related to (CXRX) include Acusphere (ACUS), Affymax (AFFY), Allarity Therapeutics (ALLR), Alseres Pharmaceuticals (ALSE), American Oriental Bioengineering (AOBI), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), Biostar Pharmaceuticals (BSPM), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), Diadexus (DDXSQ), EPIRUS Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), GlobeImmune (GBIM) and Imagenetix (IAGX). View all of CXRX's competitors..

What other stocks do shareholders of (CXRX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (CXRX) investors own include Intact Financial (IFC), Constellation Software (CSU), Concordia International (CXR), Hudbay Minerals (HBM), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), First Quantum Minerals (FM), Lundin Mining (LUN), AbbVie (ABBV) and Teck Resources (TECK)..

What is (CXRX)'s stock price today?

One share of CXRX stock can currently be purchased for approximately $0.19.